Patents by Inventor Pascal Loubiere

Pascal Loubiere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10144940
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterized in that said culture medium is chemically defined.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 4, 2018
    Assignee: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Publication number: 20170211111
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Application
    Filed: April 14, 2017
    Publication date: July 27, 2017
    Applicant: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Patent number: 9556464
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 31, 2017
    Assignee: Sanofi Pasteur
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Publication number: 20150167036
    Abstract: The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterised in that said culture medium is chemically defined.
    Type: Application
    Filed: July 2, 2013
    Publication date: June 18, 2015
    Inventors: Jérome Le Hir, Pascal Loubiere, Fabien Barbirato, Nicholas Lindley
  • Patent number: 5879915
    Abstract: The subject of the invention is the use, for the production of formic acid and/or formate starting from a culture medium containing a fermentable sugar, of a bacterial strainhaving a deficiency in the transportation or the metabolism of at least one fermentable sugar,containing an active degradation pathway for the preceding sugar via pyruvate formate lyase,capable of converting the preceding sugar mainly into formic acid and/or formate, even in the presence of a non-limiting concentration of said sugar.It also relates to a fermentation process by culture of said strain with a view to the conversion of a fermentable sugar into formic acid or formate, as well as the culture media enriched with formic acid or formate thus obtained, as well as an extraction/purification process of the formic acid in the form of one of its volatile esters, preferably ethyl formate.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: March 9, 1999
    Assignee: Lesaffre Developpement
    Inventors: Pascal Loubiere, Nicolas Lindley, Emmanuel Vidor, Patrick Taillade